Catalysis of a disulfiram metabolite, S-methyl-N.N-diethyldithiocarbamate, by CYP450 and FMO3 in human liver microsomes

M. G. Pike, Y. N. Martin, D. C. Mays, J. J. Lipsky

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

S-methyl-N,N-diethyldithiocarbamate (MeDDC) is an active metabolite in vivo of the alcohol deterrent disulfiram, but the enzymes responsible for its metabolism in humans are not known. We studied the role of both CYP450 and flavin monooxygenase (FMO) in human liver microsomes (HLM) in the metabolism of MeDDC. In HLM (pH 7.4) and in insect microsomes containing recombinant human FMO3 (pH 9.5, 0.05% TritonX-100), MeDDC sulfine was formed at a rate of 3.3±0.6 (n=11) and 11.3±0.5 (n=3) nmol/mg/min, respectively. Heating HLM at 45°C for 5 minutes (to inactivate FMO) caused 12% reduction in MeDDC sulfine formation. Likewise, 1 mM N-benzylimidazole (NBI, an inhibitor of CYP450) resulted in 93% decrease in product formation. O-Dealkylation of 7-ethoxycoumarin, a probe for CYP450, and sulfoxidation of methyl-p-tolyl sulfide, a probe for FMO, were reduced by 4% and 20% by heat inactivation and 100% and 82% by NBI, respectively. These data show that although MeDDC is an excellent substrate for FMO3, in HLM MeDDC sulfine is formed primarily by CYP450.

Original languageEnglish (US)
Pages (from-to)155
Number of pages1
JournalClinical Pharmacology and Therapeutics
Volume65
Issue number2
StatePublished - 1999

Fingerprint

dimethylaniline monooxygenase (N-oxide forming)
Disulfiram
Liver Microsomes
Catalysis
Ditiocarb
Mixed Function Oxygenases
Alcohol Deterrents
Dealkylation
Sulfides
Microsomes
Heating
Insects
methyl diethyldithiocarbamate
Hot Temperature

ASJC Scopus subject areas

  • Pharmacology

Cite this

Catalysis of a disulfiram metabolite, S-methyl-N.N-diethyldithiocarbamate, by CYP450 and FMO3 in human liver microsomes. / Pike, M. G.; Martin, Y. N.; Mays, D. C.; Lipsky, J. J.

In: Clinical Pharmacology and Therapeutics, Vol. 65, No. 2, 1999, p. 155.

Research output: Contribution to journalArticle

@article{bcb609e97d5a4481b41c369f7dcd6415,
title = "Catalysis of a disulfiram metabolite, S-methyl-N.N-diethyldithiocarbamate, by CYP450 and FMO3 in human liver microsomes",
abstract = "S-methyl-N,N-diethyldithiocarbamate (MeDDC) is an active metabolite in vivo of the alcohol deterrent disulfiram, but the enzymes responsible for its metabolism in humans are not known. We studied the role of both CYP450 and flavin monooxygenase (FMO) in human liver microsomes (HLM) in the metabolism of MeDDC. In HLM (pH 7.4) and in insect microsomes containing recombinant human FMO3 (pH 9.5, 0.05{\%} TritonX-100), MeDDC sulfine was formed at a rate of 3.3±0.6 (n=11) and 11.3±0.5 (n=3) nmol/mg/min, respectively. Heating HLM at 45°C for 5 minutes (to inactivate FMO) caused 12{\%} reduction in MeDDC sulfine formation. Likewise, 1 mM N-benzylimidazole (NBI, an inhibitor of CYP450) resulted in 93{\%} decrease in product formation. O-Dealkylation of 7-ethoxycoumarin, a probe for CYP450, and sulfoxidation of methyl-p-tolyl sulfide, a probe for FMO, were reduced by 4{\%} and 20{\%} by heat inactivation and 100{\%} and 82{\%} by NBI, respectively. These data show that although MeDDC is an excellent substrate for FMO3, in HLM MeDDC sulfine is formed primarily by CYP450.",
author = "Pike, {M. G.} and Martin, {Y. N.} and Mays, {D. C.} and Lipsky, {J. J.}",
year = "1999",
language = "English (US)",
volume = "65",
pages = "155",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Catalysis of a disulfiram metabolite, S-methyl-N.N-diethyldithiocarbamate, by CYP450 and FMO3 in human liver microsomes

AU - Pike, M. G.

AU - Martin, Y. N.

AU - Mays, D. C.

AU - Lipsky, J. J.

PY - 1999

Y1 - 1999

N2 - S-methyl-N,N-diethyldithiocarbamate (MeDDC) is an active metabolite in vivo of the alcohol deterrent disulfiram, but the enzymes responsible for its metabolism in humans are not known. We studied the role of both CYP450 and flavin monooxygenase (FMO) in human liver microsomes (HLM) in the metabolism of MeDDC. In HLM (pH 7.4) and in insect microsomes containing recombinant human FMO3 (pH 9.5, 0.05% TritonX-100), MeDDC sulfine was formed at a rate of 3.3±0.6 (n=11) and 11.3±0.5 (n=3) nmol/mg/min, respectively. Heating HLM at 45°C for 5 minutes (to inactivate FMO) caused 12% reduction in MeDDC sulfine formation. Likewise, 1 mM N-benzylimidazole (NBI, an inhibitor of CYP450) resulted in 93% decrease in product formation. O-Dealkylation of 7-ethoxycoumarin, a probe for CYP450, and sulfoxidation of methyl-p-tolyl sulfide, a probe for FMO, were reduced by 4% and 20% by heat inactivation and 100% and 82% by NBI, respectively. These data show that although MeDDC is an excellent substrate for FMO3, in HLM MeDDC sulfine is formed primarily by CYP450.

AB - S-methyl-N,N-diethyldithiocarbamate (MeDDC) is an active metabolite in vivo of the alcohol deterrent disulfiram, but the enzymes responsible for its metabolism in humans are not known. We studied the role of both CYP450 and flavin monooxygenase (FMO) in human liver microsomes (HLM) in the metabolism of MeDDC. In HLM (pH 7.4) and in insect microsomes containing recombinant human FMO3 (pH 9.5, 0.05% TritonX-100), MeDDC sulfine was formed at a rate of 3.3±0.6 (n=11) and 11.3±0.5 (n=3) nmol/mg/min, respectively. Heating HLM at 45°C for 5 minutes (to inactivate FMO) caused 12% reduction in MeDDC sulfine formation. Likewise, 1 mM N-benzylimidazole (NBI, an inhibitor of CYP450) resulted in 93% decrease in product formation. O-Dealkylation of 7-ethoxycoumarin, a probe for CYP450, and sulfoxidation of methyl-p-tolyl sulfide, a probe for FMO, were reduced by 4% and 20% by heat inactivation and 100% and 82% by NBI, respectively. These data show that although MeDDC is an excellent substrate for FMO3, in HLM MeDDC sulfine is formed primarily by CYP450.

UR - http://www.scopus.com/inward/record.url?scp=33749089655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749089655&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749089655

VL - 65

SP - 155

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 2

ER -